Walleye Trading LLC Bei Gene, Ltd. Call Options Transaction History

Walleye Trading LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 21, 2023	BUY	$179.87 - $225.13 $89,935 - $112,565	500 New	500 $89,000
Q2 2023 Aug 14, 2023	SELL	$178.3 - $266.78 $1.02 Million - $1.52 Million	-5,700 Reduced 67.06%	2,800 $499,000
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $1.66 Million - $2.11 Million	7,700 Added 962.5%	8,500 $1.83 Million
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $100,408 - $183,440	800 New	800 $175,000
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $149,136 - $233,603	-600 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $149,760 - $241,884	600 New	600 $218,000
Q3 2020 Nov 16, 2020	SELL	$189.18 - $286.44 $870,228 - $1.32 Million	-4,600 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $545,160 - $859,804	4,400 Added 2200.0%	4,600 $867,000
Q3 2019 Nov 14, 2019	SELL	$120.61 - $148.29 $735,721 - $904,569	-6,100 Reduced 96.83%	200 $24,000
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $385,236 - $630,540	3,600 Added 133.33%	6,300 $884,000
Q3 2018 Nov 14, 2018	BUY	$152.62 - $189.66 $412,074 - $512,082	2,700 New	2,700 $465,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.